China Isotope & Radiation (HKSE:01763) Change In Receivables : HK$0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is China Isotope & Radiation Change In Receivables?

China Isotope & Radiation's change in receivables for the quarter that ended in Dec. 2023 was HK$0 Mil. It means China Isotope & Radiation's Accounts Receivable stayed the same from Jun. 2023 to Dec. 2023 .

China Isotope & Radiation's change in receivables for the fiscal year that ended in Dec. 2023 was HK$-577 Mil. It means China Isotope & Radiation's Accounts Receivable increased by HK$577 Mil from Dec. 2022 to Dec. 2023 .

China Isotope & Radiation's Accounts Receivable for the quarter that ended in Dec. 2023 was HK$4,341 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. China Isotope & Radiation's Days Sales Outstanding for the six months ended in Dec. 2023 was 186.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. China Isotope & Radiation's liquidation value for the six months ended in Dec. 2023 was HK$224 Mil.

China Isotope & Radiation Change In Receivables Historical Data

The historical data trend for China Isotope & Radiation's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Isotope & Radiation Change In Receivables Chart

China Isotope & Radiation Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-464.62

-214.27

-567.27

-779.79

-576.53

China Isotope & Radiation Semi-Annual Data
	Dec15	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Receivables	Get a 7-Day Free Trial											-	-	-	-	-

China Isotope & Radiation Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0 Mil.

China Isotope & Radiation (HKSE:01763) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

China Isotope & Radiation's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	4341.347	/	4259.619	*	91
=	186.00

2. In Ben Graham's calculation of liquidation value, China Isotope & Radiation's accounts receivable are only considered to be worth 75% of book value:

China Isotope & Radiation's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	3142.481	-	6619.968	+	0.75 * 4341.347	+	0.5 * 890.516
=	224

China Isotope & Radiation Change In Receivables Related Terms

Thank you for viewing the detailed overview of China Isotope & Radiation's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

China Isotope & Radiation (HKSE:01763) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » China Isotope & Radiation Corp (HKSE:01763) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 66 Changwa Middle Street, Haidian District, Beijing, CHN, 100089

Website

https://www.china-isotope.com

China Isotope & Radiation Corp is a Chinese company. It has five operating segments: Pharmaceuticals; Radioactive source products; Irradiation; Radiation therapy equipment and related services and Other businesses. Its Pharmaceutical segment is the key revenue driver, which manufactures and sells imaging diagnostic and therapeutic radiopharmaceuticals imaging, UBT diagnostic kits, and test analyzers, and other products. Its radioactive source products segment involves the sale of medical and industrial radioactive source products and technical services. The Group's operations are carried out and majority of the Group's customers are located in the PRC.

Executives

Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Ubs Group Ag	2201 Interest of corporation controlled by you
Li Hongbo	2201 Interest of corporation controlled by you
Lianwen Ltd	2101 Beneficial owner
Invesco Advisers, Inc.	2102 Investment manager
The Bank Of New York Mellon Corporation	2201 Interest of corporation controlled by you
Invesco Hong Kong Limited	2102 Investment manager
Invesco Corporate Class Inc.	2106 Person having a security interest in shares
M&g Plc	2201 Interest of corporation controlled by you
Shanghai Industrial Holdings Limited	2201 Interest of corporation controlled by you
Shanghai Industrial Investment (holdings) Company Limited	2201 Interest of corporation controlled by you
Serenity Investment Master Fund Limited	2101 Beneficial owner
Serenity Capital Management, Ltd.	2102 Investment manager
Shanghai Pharmaceuticals Holding Co., Ltd.	2201 Interest of corporation controlled by you
S.i. Infrastructure Holdings Limited	2201 Interest of corporation controlled by you

China Isotope & Radiation (HKSE:01763) Headlines

No Headlines